Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Effects Of Sertraline Treatment For Young Children With Fxs, Laura Greiss Hess, Peter Mundy, Randi Hagerman
Effects Of Sertraline Treatment For Young Children With Fxs, Laura Greiss Hess, Peter Mundy, Randi Hagerman
Collected Faculty and Staff Scholarship
Phenotypic manifestations for young children with fragile X syndrome (FXS) include: anxiety, sensory processing challenges, global language and communication deficits and intellectual and developmental disabilities. Many of these symptoms can be treated with medications, including selective serotonin reuptake inhibitors (SSRIs). However to date a clinical trial has not been conducted for children under five years old.
This study investigated the following question: Are there group differences on developmental outcome measures for those children treated with sertraline compared to placebo?
Family Meanings, Contexts And Hopes Within A Clinical Trial, Laura Greis Hess, Cynthia Carter Ching, Randi Hagerman
Family Meanings, Contexts And Hopes Within A Clinical Trial, Laura Greis Hess, Cynthia Carter Ching, Randi Hagerman
Collected Faculty and Staff Scholarship
These qualitative analyses are a component of the clinical trial: “Effects of Sertraline Treatment for Young Children with FXS: Examination of Developmental Outcomes and Family Contexts.”
We argue that inclusion of a sociocultural perspective within the context of a clinical trial affords consideration of:
- A dynamic view of development – simultaneous consideration of biological and sociocultural factors (Vygotsky, 1978).
- Application of a bioecological framework and consideration of ever changing nested settings and contexts over time (Bronfenbrenner, 2005)